Triumvira Immunologics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2015-01-01
- Employees
- 51
- Market Cap
- -
- Website
- http://www.triumvira.com
Clinical Trials
3
Active:1
Completed:0
Trial Phases
1 Phases
Phase 1:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 1
3 (100.0%)TAC T-cells for the Treatment of Claudin 18.2 Positive Solid Tumors (TACTIC-3)
Phase 1
Active, not recruiting
- Conditions
- Metastatic Solid Tumor
- Interventions
- First Posted Date
- 2023-05-17
- Last Posted Date
- 2025-02-14
- Lead Sponsor
- Triumvira Immunologics, Inc.
- Target Recruit Count
- 113
- Registration Number
- NCT05862324
- Locations
- 🇺🇸
University of Southern California, Los Angeles, California, United States
🇺🇸University of California San Diego, San Diego, California, United States
🇺🇸University of Miami Sylvester Comprehensive Cancer Center, Miami, Florida, United States
TAC T-cells for the Treatment of HER2-positive Solid Tumors
Phase 1
Terminated
- Conditions
- Metastatic HER2 Positive Gastroesophageal Junction CancerHER2 Positive Gastric Cancer
- Interventions
- Biological: TAC01-HER2 plus pembrolizumab
- First Posted Date
- 2021-01-27
- Last Posted Date
- 2025-06-08
- Lead Sponsor
- Triumvira Immunologics, Inc.
- Target Recruit Count
- 28
- Registration Number
- NCT04727151
- Locations
- 🇺🇸
Lurie Cancer Center - Northwestern University, Chicago, Illinois, United States
🇺🇸University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
Autologous TAC T Cells Targeting CD19 in R/R Large B-Cell Lymphoma
Phase 1
Withdrawn
- Conditions
- Lymphoma, B-Cell
- First Posted Date
- 2019-03-19
- Last Posted Date
- 2022-02-23
- Lead Sponsor
- Triumvira Immunologics, Inc.
- Registration Number
- NCT03880279
News
No news found